Poison control case series documents 10-fold compounded semaglutide overdoses

A case series published in the Journal of the American Pharmacists Association describes three patients who suffered adverse reactions after administration errors with compounded semaglutide obtained from compounding pharmacies and one aesthetic spa ^[1]. Two of the three patients gave themselves ten-fold overdoses, and researchers say the mix-ups happened because the drug was dispensed in vials with separate syringes rather than in the prefilled, dose-locked pens used for brand-name products like Ozempic or Wegovy ^[1].

All three patients reported notable nausea, vomiting, and abdominal pain that lasted for days, and one patient also had headache, loss of appetite, weakness, and fatigue ^[1]. One person needed to go to a health care facility, where they were treated with an antiemetic medication and intravenous fluids and recovered ^[1]. The report was based on calls made to a regional poison control center, meaning it captures a small, specific set of cases rather than a nationwide count ^[1].

The authors point to a root cause: dosing confusion. One patient reported measuring their dose in milliliters and units instead of milligrams, the unit used for FDA-approved semaglutide products ^[1]. Because compounded semaglutide is often supplied as a vial paired with a syringe not designed specifically for the drug, patients may end up guessing at conversions between milliliters, units, and milligrams, according to the case series ^[1]. The authors also noted that one patient who got their medication from a compounding pharmacy said they received the vial and syringes without any pharmacist counseling on how to properly administer the drug ^[1].

The authors frame this as a systemic problem rather than a series of one-off patient mistakes. They write that vials of compounded semaglutide lack the safety features built into manufactured, prefilled pens, which are designed to prevent exactly this kind of large overdose ^[1]. They call for pharmacists to improve labeling, dispensing, and counseling practices, and for state boards of pharmacy and other regulators to promote proper use and dispensing of compounded semaglutide ^[1].

Why it matters for patients

Compounded semaglutide is not FDA-approved, and this case series shows one concrete way that fact can translate into real harm: a dosing error of ten times the intended amount. Patients using compounded versions may be handling a vial and a separate syringe rather than a device engineered to prevent overdosing, which raises the chance of confusing units like milliliters, units, and milligrams ^[1]. The case series also underscores that counseling from a pharmacist on how to measure and inject a dose is not guaranteed with every compounded product, according to at least one patient's account in this report ^[1]. For anyone using an injectable GLP-1 medication from any source, understanding exactly which unit of measurement their syringe uses, and matching it to their prescribed dose, is central to the safety concerns raised by these findings.

What happens next

The case series itself does not set out a timeline for regulatory action. Its authors call on pharmacy boards and other regulatory agencies to strengthen oversight of compounded semaglutide labeling and dispensing, and they urge pharmacists to increase counseling so patients feel confident administering their medication regardless of formulation ^[1]. No specific rule changes or dates are described in this report; it functions as a documented warning meant to prompt those broader policy and practice responses ^[1].